link to webcast
Category: TG4070
TG4070
TG4070 – Phase 1 trial: Evaluation in Combination with Nivolumab in Resected Non-Small Cell Lung Cancer (NSCLC) Patients TG4070 TG4070 is the second Individualized Neoantigen Therapeutic Vaccine (INTV) candidate derived from our proprietary myvac® platform, expanding into non-small cell lung cancer (NSCLC). TG4070 is being evaluated in a Phase 1 trial in combination with… Continue reading TG4070